BOSTON, Jan. 23 /PRNewswire-FirstCall/ -- PAREXEL International
Corporation (Nasdaq: PRXL) today announced its financial results for the
second quarter ended December 31, 2007.

For the three months ended December 31, 2007, PAREXEL's consolidated
service revenue increased 32.2% to a record $238.7 million, compared with
$180.5 million in the prior year period. The Company reported operating
income of $20.5 million, or 8.6% of service revenue, versus operating
income of $13.9 million, or 7.7% of service revenue, in the comparable
quarter of the prior year. Net income for the quarter totaled $11.5
million, or $0.40 per diluted share, compared with net income of
approximately $9.1 million, or $0.32 per diluted share, for the quarter
ended December 31, 2006, representing earnings per share growth of 25%.

On a segment basis, consolidated service revenue for the second quarter
of Fiscal Year 2008 was $182.7 million in Clinical Research Services (CRS),
$32.5 million in PAREXEL Consulting and Medical Communications Services
(PCMS), and $23.4 million in Perceptive Informatics, Inc.

PAREXEL's backlog increased approximately 41% year-over-year, and 13%
sequentially, to $1.778 billion at the end of the December quarter. As of
September 30, 2007, PAREXEL's backlog totaled $1.570 billion. Adding the
December quarter's gross new business wins of $486.8 million to that
amount, and subtracting $238.7 million6% 73.1%

in current quarter service revenue
and $40.1 million in cancellations, left the Company with a backlog of
$1.778 billion as of December 31, 2007. The net book-to-burn ratio in the
quarter was 1.87.

Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive
Officer stated, "During the second quarter, very strong revenue growth was
driven by increases across all business and geographic reporting segments.
The quarter's operating performance further validates our strategy and
tangibly demonstrates that the initiatives we have been focusing on over
the past few years are bearing fruit. In combination with the current
favorable outsourcing market, our proven capabilities to compete for and
win significant levels of new business leaves us well-positioned to further
improve operating margins and drive profitable growth as we go forward."

The Company issued forward-looking guidance for the third quarter of
Fiscal Year 2008 (ending March 31, 2008), for Fiscal Year 2008, and for
Calendar Year 2008. For the third quarter, the Company anticipates
reporting consolidated service revenue in the range of $240 to $250
million, using recent exchange rates, and earnings per diluted share in the
range of $0.42 to $0.44. For Fiscal Year 2008, consolidated service revenue
is expected to be in the range of $935 to $955 million, using recent
exchange rates (previously issued revenue guidance was $890 to $920
million). Earnings per diluted share for Fiscal Year 2008 are projected to
be in the range of $1.78 and $1.83 (versus previously issued guidance for
earnings per diluted share of $1.75 to $1.81). For Calendar Year 2008,
consolidated service revenue is expected to be in the range of $1.0 billion
to $1.04 billion, using recent exchange rates, and earnings per diluted
share are projected to be in the range of $1.85 to $1.94.

A conference call to discuss PAREXEL's second quarter earnings,
business, and financial outlook will begin at 10 a.m. ET, Thursday, January
24th and will be broadcast live over the internet via webcast. The webcast
may be accessed in the "Webcasts" portion of the Investor Relations section
of the Company's website at http://www.parexel.com. Users should follow the
instructions provided to ensure that the necessary audio applications are
downloaded and installed. A replay of this webcast will be archived on the
website approximately two hours after the call and will continue to be
accessible for approximately one year following the live event. To
participate via telephone, dial +1-612-332-0107 and ask to join the PAREXEL
quarterly conference call.

About the Company

PAREXEL International Corporation is a leading global
bio/pharmaceutical services organization, providing a broad range of
knowledge-based contract research, medical communications and consulting
services to the worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite time-to-market
and peak-market penetration, PAREXEL has developed significant expertise
across the development and commercialization continuum, from drug
development and regulatory consulting to clinical pharmacology, clinical
trials management, medical education and reimbursement. Perceptive
Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts, PAREXEL
operates in 64 locations throughout 51 countries around the world, and has
over 7,320 employees. For more information about PAREXEL International
visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future
results and events, including, without limitation, statements regarding
expected financial results, future growth and customer demand, such as the
guidance provided by the Company with respect to the third quarter of
Fiscal Year 2008, Fiscal Year 2008, and Calendar Year 2008. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed forward-looking statements. Without limiting
the foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "targets," and similar
expressions are also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements contained in
this release. Important factors that might cause such a difference include,
but are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating improvements
resulting from recent restructurings; the loss, modification, or delay of
contracts which would, among other things, adversely impact the Company's
recognition of revenue included in backlog; the Company's dependence on
certain industries and clients; the Company's ability to win new business,
manage growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions and to integrate newly acquired
businesses or enter into new lines of business; the impact on the Company's
business of government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical industry
and competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties; the
potential adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and other
risks. Such factors and others are discussed more fully in the section
entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for
the period ended September 30, 2007 as filed with the SEC on November 7,
2007, which "Risk Factors" discussion is incorporated by reference in this
press release. The forward- looking statements included in this press
release represent the Company's estimates as of the date of this release.
The Company specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking statements
should not be relied upon as representing the Company's estimates or views
as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation,
and Perceptive Informatics is a trademark of Perceptive Informatics, Inc.
All other names or marks may be registered trademarks or trademarks of
their respective business and are hereby acknowledged.

(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...

(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...

(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...

(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...

(Date:3/29/2017)... higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...

(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...